FHA
ABOS icon

Flagship Harbor Advisors’s Acumen Pharmaceuticals ABOS Stock Holding History

Flagship Harbor Advisors’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-350
Closed -$739 – 737
2025
Q4 		$739 Buy
+350
New +$694 ﹤0.01% 1979

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Flagship Harbor Advisors's ABOS Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of Acumen Pharmaceuticals (ABOS) in Q1 2026, closing a stake of 350 shares — an estimated $739 sold.

Flagship Harbor Advisors first reported a position in ABOS in Q4 2025 and held it in 1 quarter. The position peaked at $739 in Q4 2025. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Flagship Harbor Advisors reported no remaining Acumen Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Flagship Harbor Advisors sold 350 Acumen Pharmaceuticals shares in Q1 2026, an estimated $739.
  • Flagship Harbor Advisors first reported a position in Acumen Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Flagship Harbor Advisors's Acumen Pharmaceuticals position peaked at $739 in Q4 2025.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.